Clinical Trials | November 27, 2025
Otsuka files FDA application for first-in-class ADHD drug
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
A key highlight will be Brenntag’s qualified amino acids portfolio
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Jaypirca is making waves in the fight against B-cell malignancies
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The non-dilutive financing includes three tranches
Millions of stroke survivors across the world may soon have a new defense
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated
